These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1146 related items for PubMed ID: 26852654

  • 1. Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites.
    Wang C, Li W, Liu C, He H, Bai O.
    Blood Cells Mol Dis; 2016 Mar; 57():42-9. PubMed ID: 26852654
    [Abstract] [Full Text] [Related]

  • 2. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin.
    López-Guillermo A, Colomo L, Jiménez M, Bosch F, Villamor N, Arenillas L, Muntañola A, Montoto S, Giné E, Colomer D, Beà S, Campo E, Montserrat E.
    J Clin Oncol; 2005 Apr 20; 23(12):2797-804. PubMed ID: 15728226
    [Abstract] [Full Text] [Related]

  • 3. Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era.
    Gutiérrez-García G, Colomo L, Villamor N, Arenillas L, Martínez A, Cardesa T, García-Herrera A, Setoain X, Rodríguez S, Ghita G, Abrisqueta P, Giné E, Bosch F, Campo E, Montserrat E, López-Guillermo A.
    Leuk Lymphoma; 2010 Jul 20; 51(7):1225-32. PubMed ID: 20497002
    [Abstract] [Full Text] [Related]

  • 4. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
    Molina TJ, Canioni D, Copie-Bergman C, Recher C, Brière J, Haioun C, Berger F, Fermé C, Copin MC, Casasnovas O, Thieblemont C, Petrella T, Leroy K, Salles G, Fabiani B, Morschauser F, Mounier N, Coiffier B, Jardin F, Gaulard P, Jais JP, Tilly H.
    J Clin Oncol; 2014 Dec 10; 32(35):3996-4003. PubMed ID: 25385729
    [Abstract] [Full Text] [Related]

  • 5. Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.
    Yhim HY, Kim JS, Kang HJ, Kim SJ, Kim WS, Choi CW, Eom HS, Kim JA, Lee JH, Won JH, Shim H, Huh J, Lee DH, Suh C, Kwak JY.
    Int J Cancer; 2012 Jul 01; 131(1):235-43. PubMed ID: 21823120
    [Abstract] [Full Text] [Related]

  • 6. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
    Sehn LH, Scott DW, Chhanabhai M, Berry B, Ruskova A, Berkahn L, Connors JM, Gascoyne RD.
    J Clin Oncol; 2011 Apr 10; 29(11):1452-7. PubMed ID: 21383296
    [Abstract] [Full Text] [Related]

  • 7. Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era.
    Takahashi H, Tomita N, Yokoyama M, Tsunoda S, Yano T, Murayama K, Hashimoto C, Tamura K, Sato K, Ishigatsubo Y.
    Cancer; 2012 Sep 01; 118(17):4166-72. PubMed ID: 22213346
    [Abstract] [Full Text] [Related]

  • 8. CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy.
    Hong J, Park S, Park J, Jang SJ, Ahn HK, Sym SJ, Cho EK, Shin DB, Lee JH.
    Ann Hematol; 2012 Dec 01; 91(12):1897-906. PubMed ID: 22864685
    [Abstract] [Full Text] [Related]

  • 9. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
    El-Galaly TC, Villa D, Alzahrani M, Hansen JW, Sehn LH, Wilson D, de Nully Brown P, Loft A, Iyer V, Johnsen HE, Savage KJ, Connors JM, Hutchings M.
    Am J Hematol; 2015 Nov 01; 90(11):1041-6. PubMed ID: 26260224
    [Abstract] [Full Text] [Related]

  • 10. [Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma].
    Yao WK, Wang YP, Peng F, Zheng Y, Zou YB, Gao JN, Liu XL.
    Zhonghua Bing Li Xue Za Zhi; 2012 Dec 01; 41(12):818-22. PubMed ID: 23324230
    [Abstract] [Full Text] [Related]

  • 11. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
    Abdelhamid T, Samra M, Ramadan H, Mehessin M, Mokhtar N.
    J Egypt Natl Canc Inst; 2011 Mar 01; 23(1):17-24. PubMed ID: 22099932
    [Abstract] [Full Text] [Related]

  • 12. [Primary gastrointestinal diffuse large B-cell lymphoma: an immunohistochemical and prognostic study of 90 cases].
    Lin L, Min M, Bi CF, Wang XQ, Luo TY, Zhao S, Zhang WY, Liu WP.
    Zhonghua Bing Li Xue Za Zhi; 2011 Apr 01; 40(4):220-6. PubMed ID: 21615994
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Nodal versus extranodal diffuse large B-cell lymphoma: comparison of clinicopathologic features, immunophenotype and prognosis].
    Lu JB, Li XQ, Zhang PH, Zhou XY, Zhang TM, Li XM, Zhu XZ.
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul 01; 36(7):470-3. PubMed ID: 17845761
    [Abstract] [Full Text] [Related]

  • 15. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.
    Evens AM, Kanakry JA, Sehn LH, Kritharis A, Feldman T, Kroll A, Gascoyne RD, Abramson JS, Petrich AM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Adeimy C, Hemminger J, Bartlett NL, Mato A, Caimi PF, Advani RH, Klein AK, Nabhan C, Smith SM, Fabregas JC, Lossos IS, Press OW, Fenske TS, Friedberg JW, Vose JM, Blum KA.
    Am J Hematol; 2015 Sep 01; 90(9):778-83. PubMed ID: 26044261
    [Abstract] [Full Text] [Related]

  • 16. Biological characterization of nodal versus extranodal presentation of diffuse large B-Cell lymphoma using immunohistochemistry.
    Kim MK, Bae SH, Bae YK, Kum YS, Ryoo HM, Cho HS, Lee KH, Koh SA, Lee HY, Yun SY, Choi JH, Hyun MS.
    Clin Lymphoma Myeloma Leuk; 2011 Oct 01; 11(5):403-8. PubMed ID: 21700526
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
    Jovanovic MP, Mihaljevic B, Jakovic L, Martinovic VC, Fekete MD, Andjelic B, Antic D, Bogdanovic A, Boricic N, Terzic T, Jelicic J, Milenkovic S.
    J BUON; 2015 Oct 01; 20(3):820-8. PubMed ID: 26214636
    [Abstract] [Full Text] [Related]

  • 19. Clinical impact of bulky mass in the patient with primary extranodal diffuse large B cell lymphoma treated with R-CHOP therapy.
    Song MK, Chung JS, Sung-Yong O, Lee GW, Kim SG, Seol YM, Shin HJ, Choi YJ, Cho GJ, Shin DH, Yun EY.
    Ann Hematol; 2010 Oct 01; 89(10):985-91. PubMed ID: 20428871
    [Abstract] [Full Text] [Related]

  • 20. Treatment of gastrointestinal diffuse large B cell lymphoma in China: a 10-year retrospective study of 114 cases.
    Li X, Shen W, Cao J, Wang J, Chen F, Wang C, Zou S, Shen B, Zhao R, Li J, Shen Z.
    Ann Hematol; 2012 Nov 01; 91(11):1721-9. PubMed ID: 22733613
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.